April 17, 2026
Drug Approvals
Incruse Ellipta® (umeclidinium) – First-time authorized brand alternative
April 9, 2026 - Prasco launched an authorized brand alternative of Incruse Ellipta (umeclidinium) inhaler.
New Generics
Farxiga® (dapagliflozin) – First-time generic
April 6, 2026 - Macleods and Cipla launched AB-rated generic versions of AstraZeneca’s Farxiga (dapagliflozin) tablets.
New Generics
Qvar® (beclomethasone) – First-time generic
April 14, 2026 - Amneal launched a generic version of Teva’s Qvar (beclomethasone) HFA inhaler.
Clinical Updates
Filspari® (sparsentan) – New indication
April 14, 2026 - Travere Therapeutics announced the FDA approval of Filspari (sparsentan), to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.